Your AI-Trained Oncology Knowledge Connection!
PROVIDENCE, RI--Weekly high-dose paclitaxel (Taxol) produces response rates similar to those seen with combination chemotherapy in patients with advanced breast cancer and merits further study, William M. Sikov, MD, said at an ASCO poster session.
HOUSTON--Adding paclitaxel (Taxol) to adjuvant therapy may improve survival in inflammatory breast cancer, Massimo Cristofanilli, MD, of M.D. Anderson Cancer Center, reported at the ASCO meeting.
We agree with the need to reexamine the routine use of axillary dissection in the management of breast cancer patients, as advocated by Manjeet Chadha and Deborah Axelrod, in their article, "Is Axillary Dissection Always Indicated in Invasive
OXFORD, UK--The latest 5-year metaanalysis by the Early Breast Cancer Clinical Trialists’ Collaborative Group suggests that up to 20,000 additional lives could be saved each year worldwide if physicians prescribed adjuvant tamoxifen (Nolvadex) to all early breast cancer patients who could benefit, including premenopausal women.
ASCO--In two phase III trials, the anti-HER-2/neu monoclonal antibody (MoAB) Herceptin (trastuzumab, Genen-tech) showed significant activity both as a single agent and in combination with traditional cytotoxic chemotherapy in the treatment of HER-2/neu overexpressing metastatic breast cancer.
WASHINGTON--Feedback indicates that the National Cancer Institute did quite well in equipping counselors in advance to deal with questions posed by women about the ability of tamoxifen (Nolvadex) to prevent breast cancer, NCI director Richard D. Klausner, MD, told a Senate subcommittee.
ASCO--Postmenopausal women with osteoporosis who took raloxifene (Evista) for 2½ years to prevent fractures also had a significant 70% reduction in breast cancer risk, according to results of the Multiple Outcomes of Raloxifene Evaluation (MORE), reported at ASCO.
A Carnegie Mellon University study of women with breast cancer has shown that those with strong social or family networks and a good relationship with their oncologist may not benefit from participation in emotional support groups and may, in fact,
Women with common variations in the class of enzyme known as glutathione S-transferase (GST), which detoxify carcinogens, are at increased risk of developing breast cancer, according to researchers at the Johns Hopkins School of Public Health.
NUTLEY, NJ--Hoffmann-La Roche Inc. has received accelerated approval from the Food and Drug Administration for Xeloda (capecitabine), making it the first approved oral anticancer drug for patients with metastatic breast cancer whose tumors are resistant to standard chemotherapy with paclitaxel (Taxol) and an anthracycline-containing regimen.
In 1996, the total in-hospital charges for the primary treatment of women with breast cancer with a modified radical mastectomy averaged $10,000 throughout the United States. The total charge (hospital plus physician’s fees) varied by 95% between the high charge reported in New York ($12,690) and the low charge in Michigan ($6,510). The hospital portion of the bill averaged 65% of the total and ranged from 51% in New York to 74% in Virginia. The average length of stay for these women was 2.39 days and ranged from 3.18 days in New York to 1.69 and 1.66 days in Washington and Arizona, respectively. The average charge for a partial mastectomy was $8,760, with notable variations between states. The Texas total charge was the highest ($12,890, some 47% above the US norm) and more than twice the low charge in Ohio ($6,080, 31% below the US average). The physicians’ charges averaged $3,330 for the country as a whole and accounted for 38% of the bill. This proportion ranged from 46% of the total in New York to 70% in Indiana and Colorado. The average length of hospitalization for a partial mastectomy was 1.84 days. On average, women remained in the hospital for the longest time in New Jersey (2.78 days) and for the shortest time in Oregon and Massachusetts (1.40 days and 1.45 days, respectively).[ONCOLOGY 12(6):889-902, 1998]
Methods for detecting breast cancer are evolving as new technology provides a wider range of options for screening and definitive diagnosis. In addition to mammography and physical examination, screening techniques now include ultrasonography, technetium-99m sestamibi nuclear scanning, and magnetic resonance imaging.
A decade has passed since the first stereotactic-guided histologic breast biopsy was performed. Initially, the large-scale implementation of this technique met with a great deal of resistance from most surgeons, and more surprisingly, from many breast radiologists in academia.
PRINCETON, NJ--The Marsupial Pouch, designed to help women cope with temporary surgical drains following breast surgery, is being distributed nationwide by Derma Sciences Inc. Designed by a two-time breast cancer survivor, the product is an adjustable terry cloth belt with an attachable pouch to house the drainage tubes.
NEW ORLEANS--High concentrations of insulin-like growth factor I (IGF-I) in the circulation identify the men most at risk of prostate cancer as well as the women at highest risk of premenopausal breast cancer, according to results presented at the 89th annual meeting of the American Association for Cancer Research (AACR).
This paper will address various issues relevant to core-needle biopsy of the breast under stereotactic imaging guidance. Patient and equipment selection, indications, contraindications, complications, limitations, and advantages will be discussed. The role of stereotactic core biopsy in patient management will also be addressed.
NEW ORLEANS--Most women with a family history of breast cancer have a familial predisposition to the disease, rather than true hereditary breast cancer. A comprehensive family history should guide the recommendations regarding testing for a genetic mutation, which, at about $2,400, should not be taken lightly, said speakers at an AMA-sponsored program on genetic medicine and the practicing physician.
A new study from the Medical College of Wisconsin Cancer Center has shown that celebrity role models can influence decisions about medical care. The national study of breast cancer treatment patterns following Mrs. Ronald Reagan’s decision to have a mastectomy in 1987 showed that 25% fewer women than expected underwent lumpectomy or breast-conserving surgery.
I was quite disappointed with Dr. Graham A. Colditz ’s review of the literature concerning the use of estrogen replacement therapy in patients with breast cancer, which appeared in the November 1997 issue of ONCOLOGY (pp 1491-1497).
Since physicians have stressed complete rehabilitation after breast cancer treatment, including breast reconstruction and psychosocial aspects, it follows that young women who have undergone such treatment may wish to resume their life roles, which often include motherhood. Consequently, the issue of pregnancy after breast cancer treatment has assumed paramount importance. This pertinent, accurate review of such a complex issue can be so brief because there are so few data on the subject. Given the diversity of the issues presented in the review, it is helpful to consider them individually.
Breast cancer, the most common malignancy in women, frequently develops during the premenopausal years. The great majority of these breast cancers can be successfully treated, and the decision to have children remains a real and important consideration. The relationship between breast cancer and a subsequent pregnancy is complex, and decisions regarding one may ultimately affect the course or outcome of the other.
Women face numerous issues if they either contemplate childbearing or become pregnant after the diagnosis of breast cancer. Based on a search of the English medical literature from 1966 to 1997, we make the following
FORT LAUDERDALE, Fla--The much-anticipated, prospective, comprehensive outcomes data base of the National Comprehensive Cancer Network (NCCN), a consortium of 16 US cancer centers, is now up and running, and includes data on almost 400 patients with newly diagnosed breast cancer collected at five NCCN sites over 3 months.
Alterations in a gene discovered last year by UT Southwestern Medical Center in Dallas scientists have been linked to breast, ovarian, and uterine cancers, the researchers reported in the February issue of Human Molecular Genetics.
WASHINGTON--Researchers terminated the treatment portion of the Breast Cancer Prevention Trial (BCPT) in late March, 14 months earlier than expected, after the study’s independent monitoring committee determined that patients receiving tamoxifen (Nolvadex) had a 45% reduction in breast cancer incidence, compared to the placebo arm.
